Congenital adrenal hyperplasia, disorders of sex development, and infertility in patients with POR gene pathogenic variants: a systematic review of the literature.
CAH
Congenital adrenal hyperplasia
DSD
Disorders of sex development
Fertility
POR
Sperm parameters
TART
Testicular adrenal rest tumor
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
21
02
2022
accepted:
23
06
2022
pubmed:
18
7
2022
medline:
12
1
2023
entrez:
17
7
2022
Statut:
ppublish
Résumé
P450 oxidoreductase (POR) deficiency (PORD) is characterized by congenital adrenal hyperplasia (CAH) and disorders of sex development (DSD) in both sexes. PORD can also associate with skeletal defects. However, the prevalence of these phenotypes is unknown. To evaluate the prevalence of CAH, DSD, and infertility of patients with POR gene pathogenic variants by a systematic review of the literature. The literature search was performed through PubMed, MEDLINE, Cochrane, Academic One Files, Google Scholar, and Scopus databases. All studies reporting information on CAH, DSD, testicular adrenal rest tumor (TARTs), and fertility in patients with POR gene pathogenic variants were included. Finally, the prevalence of abnormal phenotypes was calculated. Of the 246 articles initially retrieved, only 48 were included for a total of 119 (46 males and 73 females) patients with PORD. We also included the case of a male patient who consulted us for CAH and TARTs but without DSD. This patient, found to be a carrier of combined heterozygous POR mutation, reached fatherhood spontaneously. All the patients found had CAH. The presence of DSD was found in 65.2%, 82.1%, and 82.1% of patients with compound heterozygosity, homozygosity, or monoallelic heterozygous variants, respectively. The prevalence was significantly higher in females than in males. The prevalence of TARTs in patients with PORD is 2.7%. Only 5 women with PORD became pregnant after assisted reproductive techniques and delivered a healthy baby. Except for the recently reported proband, no other studies focused on male infertility in patients with POR gene variants. This systematic review of the literature reports the prevalence of CAH, DSD, and TARTs in patients with PORD. The unknown prevalence of POR gene pathogenetic variants and the paucity of studies investigating fertility do not allow us to establish whether PORD is associated with infertility. Further studies on both women and men are needed to clarify this relationship.
Sections du résumé
BACKGROUND
BACKGROUND
P450 oxidoreductase (POR) deficiency (PORD) is characterized by congenital adrenal hyperplasia (CAH) and disorders of sex development (DSD) in both sexes. PORD can also associate with skeletal defects. However, the prevalence of these phenotypes is unknown.
AIM
OBJECTIVE
To evaluate the prevalence of CAH, DSD, and infertility of patients with POR gene pathogenic variants by a systematic review of the literature.
METHODS
METHODS
The literature search was performed through PubMed, MEDLINE, Cochrane, Academic One Files, Google Scholar, and Scopus databases. All studies reporting information on CAH, DSD, testicular adrenal rest tumor (TARTs), and fertility in patients with POR gene pathogenic variants were included. Finally, the prevalence of abnormal phenotypes was calculated.
RESULTS
RESULTS
Of the 246 articles initially retrieved, only 48 were included for a total of 119 (46 males and 73 females) patients with PORD. We also included the case of a male patient who consulted us for CAH and TARTs but without DSD. This patient, found to be a carrier of combined heterozygous POR mutation, reached fatherhood spontaneously. All the patients found had CAH. The presence of DSD was found in 65.2%, 82.1%, and 82.1% of patients with compound heterozygosity, homozygosity, or monoallelic heterozygous variants, respectively. The prevalence was significantly higher in females than in males. The prevalence of TARTs in patients with PORD is 2.7%. Only 5 women with PORD became pregnant after assisted reproductive techniques and delivered a healthy baby. Except for the recently reported proband, no other studies focused on male infertility in patients with POR gene variants.
CONCLUSION
CONCLUSIONS
This systematic review of the literature reports the prevalence of CAH, DSD, and TARTs in patients with PORD. The unknown prevalence of POR gene pathogenetic variants and the paucity of studies investigating fertility do not allow us to establish whether PORD is associated with infertility. Further studies on both women and men are needed to clarify this relationship.
Identifiants
pubmed: 35842891
doi: 10.1007/s40618-022-01849-9
pii: 10.1007/s40618-022-01849-9
pmc: PMC9829634
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Informations de copyright
© 2022. The Author(s).
Références
Am J Med Genet A. 2004 Aug 1;128A(4):333-9
pubmed: 15264278
Nat Genet. 2004 Mar;36(3):228-30
pubmed: 14758361
Hormones (Athens). 2016 Apr;15(2):277-282
pubmed: 27376429
Fertil Steril. 2019 Jan;111(1):7-12
pubmed: 30611420
Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):536-41
pubmed: 26969897
J Clin Endocrinol Metab. 2005 Jan;90(1):414-26
pubmed: 15483095
Clin Exp Obstet Gynecol. 2016;43(6):902-904
pubmed: 29944250
J Biol Chem. 2003 Jan 31;278(5):2837-44
pubmed: 12444089
J Assist Reprod Genet. 2020 Oct;37(10):2503-2511
pubmed: 32725309
J Clin Endocrinol Metab. 2009 Dec;94(12):4992-5000
pubmed: 19837910
Endocr Rev. 2022 Jan 12;43(1):91-159
pubmed: 33961029
J Ovarian Res. 2021 Feb 1;14(1):22
pubmed: 33526062
Int J Mol Sci. 2019 Sep 17;20(18):
pubmed: 31533357
Hum Reprod. 2020 Apr 28;35(4):939-949
pubmed: 32242900
J Pediatr Endocrinol Metab. 2009 May;22(5):469-75
pubmed: 19618668
J Biol Chem. 2005 Apr 8;280(14):13265-71
pubmed: 15687493
Ann Pediatr Endocrinol Metab. 2020 Jun;25(2):97-103
pubmed: 32615689
Eur J Endocrinol. 2012 Mar;166(3):441-9
pubmed: 22157069
J Clin Endocrinol Metab. 2010 Nov;95(11):5110-21
pubmed: 20719839
J Clin Endocrinol Metab. 2006 Jul;91(7):2643-9
pubmed: 16608896
Endocr Res. 2004 Nov;30(4):957-64
pubmed: 15666853
Gynecol Endocrinol. 2018 May;34(5):385-388
pubmed: 29069987
Eur J Endocrinol. 2018 Sep;179(3):R125-R141
pubmed: 29880708
Eur J Pediatr. 2017 Oct;176(10):1393-1404
pubmed: 28879515
Fertil Steril. 1987 Apr;47(4):664-70
pubmed: 3032693
Lancet. 2017 Nov 11;390(10108):2194-2210
pubmed: 28576284
Indian J Endocrinol Metab. 2017 Mar-Apr;21(2):360-362
pubmed: 28459039
Lancet. 2004 Jun 26;363(9427):2128-35
pubmed: 15220035
Horm Res Paediatr. 2018;89(5):292-310
pubmed: 29874650
Ann Lab Med. 2017 Nov;37(6):559-562
pubmed: 28841001
J Endocrinol Invest. 2000 Jan;23(1):23-7
pubmed: 10698047
Nat Genet. 1997 Oct;17(2):201-5
pubmed: 9326943
Biochem Biophys Res Commun. 2011 Sep 9;412(4):572-7
pubmed: 21843508
J Endocrinol Invest. 2021 Nov;44(11):2395-2405
pubmed: 33677812
Pediatr Res. 2006 Feb;59(2):276-80
pubmed: 16439592
Mol Endocrinol. 1999 Jan;13(1):167-75
pubmed: 9892022
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10619-23
pubmed: 7479852
Eur J Endocrinol. 2010 Dec;163(6):919-24
pubmed: 20844025
BMJ Case Rep. 2013 Jul 22;2013:
pubmed: 23878291
J Clin Endocrinol Metab. 2009 May;94(5):1665-70
pubmed: 19258407
BMJ Case Rep. 2020 Sep 29;13(9):
pubmed: 32994263
J Clin Endocrinol Metab. 2009 May;94(5):1723-31
pubmed: 19258400
J Clin Endocrinol Metab. 2001 Jul;86(7):3070-8
pubmed: 11443169
J Ovarian Res. 2017 Mar 14;10(1):16
pubmed: 28288674
Am J Med Genet A. 2004 Jul 30;128A(3):223-31
pubmed: 15216541
J Clin Endocrinol Metab. 2015 Jun;100(6):2303-13
pubmed: 25822101
Ann N Y Acad Sci. 2005 Dec;1061:100-8
pubmed: 16467261
Arq Bras Endocrinol Metabol. 2012 Nov;56(8):578-85
pubmed: 23295302
Hong Kong Med J. 2010 Feb;16(1):59-62
pubmed: 20124576
J Endocrinol Invest. 2021 Oct;44(10):2219-2226
pubmed: 33666875
Am J Case Rep. 2015 Dec 16;16:882-5
pubmed: 26670660
Hormones (Athens). 2021 Jun;20(2):293-298
pubmed: 33123976
Endocr Connect. 2021 Jun 16;10(6):620-629
pubmed: 34009138
Orphanet J Rare Dis. 2019 Dec 30;14(1):299
pubmed: 31888681
Front Genet. 2020 Aug 21;11:976
pubmed: 32973886
J Clin Endocrinol Metab. 2001 Dec;86(12):5721-8
pubmed: 11739428
J Steroid Biochem Mol Biol. 2021 Jul;211:105899
pubmed: 33864926
J Clin Endocrinol Metab. 2012 Feb;97(2):E257-67
pubmed: 22162478
Neth J Med. 2011 Jun;69(6):281-3
pubmed: 21868813
J Pediatr Orthop B. 2008 Sep;17(5):241-5
pubmed: 19471176
J Clin Endocrinol Metab. 2008 Sep;93(9):3584-8
pubmed: 18559916
J Clin Endocrinol Metab. 2011 Mar;96(3):E453-62
pubmed: 21190981
J Biol Chem. 1998 Feb 6;273(6):3158-65
pubmed: 9452426
J Clin Endocrinol Metab. 2016 Dec;101(12):4789-4798
pubmed: 27603900
Arch Endocrinol Metab. 2016 Oct 10;60(5):500-504
pubmed: 27737328
Am J Med Genet A. 2006 Sep 1;140A(17):1797-803
pubmed: 16906539
Eur J Endocrinol. 2021 Apr;184(4):487-501
pubmed: 33524003
Eur J Pediatr. 2009 Jul;168(7):877-80
pubmed: 18853185
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 32060549
J Med Genet. 2000 Jan;37(1):26-32
pubmed: 10633130
Med Princ Pract. 2014;23(4):384-6
pubmed: 24334858
J Clin Endocrinol Metab. 2010 Jul;95(7):3418-27
pubmed: 20410220
Am J Hum Genet. 2005 May;76(5):729-49
pubmed: 15793702
J Endocrinol Invest. 2022 Feb;45(2):347-359
pubmed: 34341969
Steroids. 1997 Jan;62(1):133-42
pubmed: 9029728
Clin Endocrinol (Oxf). 2016 Jun;84(6):830-6
pubmed: 26666213
J Clin Endocrinol Metab. 1990 May;70(5):1408-13
pubmed: 2335578